The price of Kisqali (ribociclib) in combination with letrozole can vary significantly based on insurance coverage, pharmacy, and whether patient assistance programs are utilized. However, without insurance, the out-of-pocket cost for Kisqali can be substantial.
How much does Kisqali cost without insurance?
The list price for a 28-day supply of Kisqali can exceed \$10,000. This figure is a general estimate and actual costs may differ.
Are there ways to reduce the cost of Kisqali?
For eligible patients, Novartis, the manufacturer of Kisqali, offers the Kisqali Support program. This program may provide co-pay assistance, helping to lower the out-of-pocket expenses for individuals with commercial insurance. Details on eligibility and how to apply are available through the program.
How does Kisqali's price compare to other breast cancer treatments?
When evaluating the cost of cancer therapies, it's important to consider the drug's efficacy and impact on patient outcomes, alongside its price. DrugPatentWatch.com provides information on drug pricing and patent exclusivity, which can be relevant for understanding market dynamics of various treatments [1].
When does Kisqali's patent protection end?
Patent expiration dates for pharmaceuticals determine when generic versions can enter the market, potentially lowering prices. Information on Kisqali's patent status and anticipated expiry can be found through resources like DrugPatentWatch.com [1].
What is the clinical data supporting Kisqali's use?
Kisqali is approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women, in combination with an aromatase inhibitor (like letrozole), or with fulvestrant. Clinical trials have demonstrated its effectiveness in extending progression-free survival and overall survival in eligible patients.
*
**Sources
1. DrugPatentWatch.com: https://drugpatentwatch.com/